FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in lung cancer
Copenhagen, Denmark, 24 March 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has received approvals to initiate the phase II trial in lung cancer. The trial is expected to enrol first patient in Q2.Following approval from the Danish Medicines Agency and Ethical Committee, FluoGuide will initiate enrolment a phase II trial in lung cancer in collaboration with Department of Cardiothoracic Surgery at the University Hospital, Rigshospitalet, in Denmark. The phase II trial is designed to enrol up to 24 patients with non-small cell lung cancer (